New Zealand markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
91.46+0.20 (+0.22%)
At close: 04:00PM EDT
91.58 +0.12 (+0.14%)
After hours: 06:53PM EDT

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees110,000

Key executives

NameTitlePayExercisedYear born
Dr. Vasant NarasimhanChief Exec. Officer5.08MN/A1976
Mr. Harry KirschChief Financial Officer2.83MN/A1965
Dr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer1.38MN/A1968
Ms. Karen L. HaleChief Legal Officer2.07MN/A1968
Dr. Robert Kowalski Pharm.D.Chief People & Organization Officer1.19MN/A1968
Mr. Steffen Lang Ph.D.Pres of Operations2.34MN/A1967
Ms. Marie-France TschudinPres of Innovative Medicines International & Chief Commercial Officer2.56MN/A1971
Mr. Richard SaynorChief Exec. Officer of Sandoz1.86MN/A1967
Dr. James E. Bradner M.D.Pres of Novartis Institutes for Biomedical Research3.07MN/A1972
Paul PenepentHead of Group Financial Reporting and AccountingN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate governance

Novartis AG’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.